<DOC>
	<DOCNO>NCT01376258</DOCNO>
	<brief_summary>Adherence length treatment 5-alpha reductase inhibitor ( 5ARI ) therapy may associate improved clinical outcome patient enlarge prostate ( EP ) low health care relate cost . The objective study quantify 1 . ) relationship 5ARI adherence length therapy likelihood acute urinary retention ( AUR ) , prostate-related surgery ( emergency non-emergency ) , clinical progression ( define AUR and/or prostate-related surgery ) ; 2 . ) monthly EP-related , medical cost Medicaid Medicare population . The null hypothesis difference observe outcomes cost patient adhere long-term 5ARI therapy . The test hypothesis patient high level adherence 5ARI long period time experience significantly few adverse outcome significantly low treatment cost . The data source analysis MarketScan database , contain medical pharmacy claim commercial health plan member Medicare recipient . Medical pharmacy claim data source directly health plan employer . The database represent approximately 18 20 million individual annually nearly 22 million Medicaid enrollee multiple state . The database include Medicare-covered portion payment , employer-paid portion , out-of-pocket expense pay beneficiary . The study design retrospective cohort analysis . Each patient 's index date define date first fill 5ARI prescription .</brief_summary>
	<brief_title>Benefits Adherence 5-alpha Reductase Inhibitor Treatment Men With Enlarged Prostate : An Assessment Medicare Medicaid Patients Using MarketScan Database</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>Male Age 65 old A diagnostic claim BPH ( ICD9CM code 222.2x 600.xx ) A prescription claim 5ARI least 60 day observation period Continuous eligibility 6 month prior least 91 day index date A prostate cancer diagnosis A procedure cost prostaterelated surgical procedure prior index date</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>benign prostatic hyperplasia</keyword>
	<keyword>acute urinary retention</keyword>
	<keyword>adherence</keyword>
	<keyword>5-alpha reductase inhibitor</keyword>
	<keyword>enlarge prostate</keyword>
	<keyword>surgery</keyword>
</DOC>